Profound Medicl (NYSE:PROF) had its price target upped by Raymond James from $38.00 to $43.00 in a research report issued on Friday, The Fly reports. The firm presently has a “strong-buy” rating on the stock. Raymond James’ target price would suggest a potential upside of 172.50% from the stock’s current price.
Other equities research analysts have also issued reports about the stock. Mackie lowered shares of Profound Medicl from a “buy” rating to a “hold” rating in a report on Tuesday, April 7th. Zacks Investment Research lowered shares of Profound Medicl from a “hold” rating to a “sell” rating in a report on Tuesday, July 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $24.00.
PROF opened at $15.78 on Friday. Profound Medicl has a 12 month low of $5.59 and a 12 month high of $20.60. The business’s 50-day moving average price is $15.46 and its 200-day moving average price is $13.52.
Profound Medicl (NYSE:PROF) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.03. The company had revenue of $1.16 million for the quarter, compared to the consensus estimate of $1.62 million.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in Profound Medicl during the 4th quarter valued at $147,000. Bank of America Corp DE purchased a new position in shares of Profound Medicl during the fourth quarter valued at about $57,000. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Profound Medicl during the first quarter valued at about $148,000. Raymond James & Associates bought a new position in Profound Medicl in the first quarter worth about $100,000. Finally, UBS Group AG lifted its holdings in Profound Medicl by 406.4% in the first quarter. UBS Group AG now owns 3,545 shares of the company’s stock worth $34,000 after buying an additional 2,845 shares during the period.
About Profound Medicl
Profound Medical Corp. operates as a medical technology company focuses on magnetic resonance guided ablation procedures in Canada, Germany, and Finland. It is developing a treatment to ablate the prostate gland in prostate cancer patients, treatment of uterine fibroids and nerves, and palliative pain treatment for patients with metastatic bone disease.
Recommended Story: Derivative
Receive News & Ratings for Profound Medicl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medicl and related companies with MarketBeat.com's FREE daily email newsletter.